Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E9HQ
|
|||
| Former ID |
DCL000618
|
|||
| Drug Name |
R7334
|
|||
| Synonyms |
R 7334; 2-Nitro-6,7,8,9-tetrahydronaphtho(1,2-b)furan; 2-nitro-6,7,8,9-tetrahydrobenzo[g][1]benzofuran; 6,7,8,9-Tetrahydro-2-nitronaphtho(1,2-b)furan
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Macular degeneration [ICD-11: 9B78.3; ICD-10: H35.3; ICD-9: 362.5] | Phase 1 | [1] | |
| Company |
Roche
|
|||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Placenta growth factor (PlGF) | Target Info | . | [2] |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| PI3K-Akt signaling pathway | ||||
| Focal adhesion | ||||
| Pathways in cancer | ||||
| NetPath Pathway | TSH Signaling Pathway | |||
| Pathway Interaction Database | VEGFR1 specific signals | |||
| Reactome | VEGF ligand-receptor interactions | |||
| VEGF binds to VEGFR leading to receptor dimerization | ||||
| WikiPathways | Focal Adhesion | |||
| Signaling by VEGF | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00702494) Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Roche (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.